No profile data available.
VivoSim Labs, Inc. (VIVS) is a healthcare company in the medication development research industry, based in San Diego, United States, with about 15 full-time employees.
It reported revenue of $144,000 for fiscal year 2025, up 32.1% from fiscal year 2024, and net income of -$2.49 million. In Q3 2026 (the quarter ended December 31, 2025) revenue was $26,000, up 8.3% from a year before. Its market capitalization was $2.99 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
, a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
VivoSim Labs reported $144,000 in revenue for fiscal year 2025, up 32.1% from $109,000 in fiscal year 2024. In Q3 2026 revenue was $26,000.
$2.99 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medication development research) include Ernexa Therapeutics Inc. (ERNA), HCW Biologics Inc. (HCWB), Vaccinex, Inc. (VCNX), Theralink Technologies, Inc. (THER).